Business Context and Reporting Period
Company: Greatbatch, Inc. (Note: Input metadata referenced "Integer Holdings Corp," but the filing text identifies the registrant as Greatbatch, Inc.)
Filing Type: Form 10-K (Annual Report)
Fiscal Year End: January 2, 2009 (53-week fiscal year)
Business Overview: Greatbatch is a leading developer and manufacturer of critical components for medical devices (Cardiac Rhythm Management, Neuromodulation, Vascular Access, Orthopedics) and electrochemical solutions (batteries, wireless sensors) for demanding industrial applications. The company operates two reportable segments: Implantable Medical Components (IMC) and Electrochem Solutions.
Key Financial Metrics
| Metric | Fiscal 2008 (Ended Jan 2, 2009) | Fiscal 2007 (Ended Dec 28, 2007) |
|---|---|---|
| Total Sales | $546.6 million | $318.7 million |
| Net Income | $18.6 million | $15.1 million |
| Diluted EPS | $0.81 | $0.67 |
| Operating Income | $34.9 million | $20.0 million |
| Operating Margin | 6.4% | 6.3% |
| Net Margin | 3.4% | 4.7% |
| Cash Flow from Operations | $57.1 million | $43.0 million |
| Long-Term Debt | $352.9 million | $241.2 million |
| Cash and Equivalents | $22.1 million | $33.5 million |
| Working Capital | $142.2 million | $116.8 million |
| Total Assets | $848.9 million | $663.9 million |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 71% to a record $546.6 million, driven by $208.2 million in incremental revenue from seven acquisitions completed in 2007 and 2008 (including Precimed and the DePuy Chaumont facility) and 7% organic growth.
- Segment Expansion: The IMC segment grew 73% to $468.1 million, entering the Orthopedic market ($142.4 million) and expanding Vascular Access ($47.4 million). The Electrochem segment grew 60% to $78.5 million.
- Profitability Impact: While net income rose 23%, net margin declined from 4.7% to 3.4%. This was due to significant non-recurring charges, including $2.2 million in acquired in-process research and development (IPR&D) expenses, $6.4 million in inventory step-up amortization, and $8.3 million in facility shutdown/consolidation costs.
- Debt Increase: Long-term debt increased by approximately $111.7 million to fund acquisitions and working capital, primarily through a $235 million revolving credit facility.
Guidance, Outlook, and Risks
- 2009 Sales Outlook: Management projects full-year 2009 sales in the range of $550 million to $600 million.
- Cost Savings: Ongoing facility consolidation and integration initiatives are expected to yield $5 million to $6 million in annual cost savings, fully realized by 2010. Remaining consolidation costs are estimated at $10 million to $13 million for 2009.
- Accounting Changes: New accounting standards (FSP APB 14-1) effective in 2009 are expected to increase non-cash interest expense by $7 million to $8 million, potentially reducing diluted EPS by $0.19 to $0.22.
- Key Risks:
- Customer Concentration: Three customers (Boston Scientific, Medtronic, St. Jude Medical) accounted for 44% of 2008 sales.
- Intangible Assets: Intangible assets represent 50% of total assets ($428.6 million), creating risk of impairment charges.
- Raw Materials: Reliance on limited suppliers for critical materials (lithium, tantalum, platinum) exposes the company to price volatility.
- Market Conditions: Exposure to the cyclical oil and gas industry (Electrochem) and potential softening in elective orthopedic surgeries.
- Legal Contingencies: Pending appeal of a patent infringement lawsuit (Pressure Products) regarding FlowGuard introducers; potential loss up to $1.7 million in a separate proprietary information dispute.
Investor Verification Checklist
- Acquisition Integration: Verify the realization of projected synergies and cost savings from the seven acquisitions made in 2007-2008.
- Customer Concentration: Monitor the stability of relationships with the top three customers representing 44% of revenue.
- Debt Covenants: Confirm continued compliance with leverage ratios (max 5.0:1 through Sept 2009, then 4.5:1) and interest coverage ratios (min 3.0:1) under the revolving credit facility.
- Intangible Asset Valuation: Assess the annual impairment testing of goodwill ($302.2 million) and indefinite-lived intangibles ($36.1 million).
- 2009 EPS Impact: Evaluate the financial impact of the new convertible debt accounting standard on 2009 earnings.
- French VAT Receivable: Track the collection of the $11.6 million value-added tax receivable from the French government related to the Chaumont facility.